Vor Biopharma (NASDAQ:VOR) Shares Down 3.8% – Time to Sell?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) dropped 3.8% on Wednesday . The stock traded as low as $1.99 and last traded at $2.00. Approximately 4,923,423 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 4,588,243 shares. The stock had previously closed at $2.08.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. HC Wainwright raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 30th. Zacks Research raised shares of Vor Biopharma to a “strong sell” rating in a report on Tuesday, August 12th. Finally, Wall Street Zen cut shares of Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Vor Biopharma Stock Down 3.8%

The firm has a market capitalization of $253.36 million, a price-to-earnings ratio of -0.15 and a beta of 2.06. The business’s fifty day moving average is $2.11.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Tuesday, August 12th. The company reported ($2.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($1.61).

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.